What's Happening?
A significant study of the UK's HPV vaccination program has revealed that the vaccine, administered to schoolgirls since 2008, has nearly eradicated cervical cancer deaths among young women. The research, published in The Lancet, indicates that girls vaccinated
at ages 12 or 13 now face an almost nonexistent risk of dying from cervical cancer before the age of 30. Between 2020 and 2024, there were no recorded cervical cancer deaths among women aged 20 to 24, a demographic where approximately two dozen deaths would have been expected without vaccination. Researchers estimate that around 200 lives have been saved so far, with the potential for more as vaccinated cohorts age. Despite these promising results, vaccination coverage is slipping, with only 76% of girls in England vaccinated by age 15 in 2024-2025, falling short of the 90% target set by the World Health Organization (WHO). Efforts are underway to increase vaccination rates and include boys in the program to further reduce transmission.
Why It's Important?
The findings underscore the transformative impact of the HPV vaccine in preventing cervical cancer, a disease that remains the fourth most common cancer among women globally. In the UK, approximately 3,300 women are diagnosed with cervical cancer annually, while in the US, the number is about 13,500. The success of the UK's vaccination program highlights the potential for similar outcomes in other countries, emphasizing the importance of achieving high vaccination coverage. The inclusion of boys in the vaccination program since 2019 further aids in reducing transmission and protecting against various cancers. The study's results could influence public health policies and encourage other nations to adopt or expand similar vaccination programs, aiming to eliminate cervical cancer as a public health issue by 2040.
What's Next?
To maintain and enhance the success of the HPV vaccination program, targeted actions are necessary to address areas with low vaccine uptake. Public health officials are expanding catch-up campaigns and introducing HPV self-testing to reach those who have not yet been screened. These efforts aim to increase vaccination rates to meet the WHO's 90% target, which is crucial for effectively eliminating cervical cancer. The ongoing inclusion of boys in the vaccination program will continue to play a vital role in reducing transmission rates. As vaccinated cohorts age, the long-term impact of the program will become more apparent, potentially leading to further reductions in cervical cancer incidence and mortality.
